Clinical trials · California
Metastatic Lung Non-Small Cell Carcinoma clinical trials in California
We’re tracking 84 recruiting metastatic lung non-small cell carcinoma studies with a site in California — including Phase 1, Phase 1/Phase 2 and Phase 2/Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
San Francisco, CaliforniaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Los Angeles, CaliforniaAges 18 years+ - NCT07012031RecruitingPhase 1/Phase 2
Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer
This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Orange, CaliforniaAges 18 years+ - NCT07160335RecruitingPhase 1
Testing a potential biosimilar for multiple resected solid tumors
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
San Bernardino, CaliforniaAges 18–85 - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Orange, CaliforniaAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Los Angeles, CaliforniaAges 18 years+
Metastatic Lung Non-Small Cell Carcinoma trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting metastatic lung non-small cell carcinoma studies listed above.
- Cancer and Blood Specialty Clinic
- City of Hope Comprehensive Cancer Center
- HCA
- Los Angeles Cancer Network
- Oncology Physicians Network (OPN) - San Bernardino
- OPN Healthcare, Inc.
- Providence Medical Foundation
- Research Site
What taking part in a metastatic lung non-small cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Lung Non-Small Cell Carcinoma trials in other states
Common questions
- Are there metastatic lung non-small cell carcinoma clinical trials in California?
- Yes. We're currently tracking 84 recruiting metastatic lung non-small cell carcinoma studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic lung non-small cell carcinoma study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic lung non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic lung non-small cell carcinoma studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.